New drug combo aims to outperform standard care in aggressive lung cancer
Disease control
Not yet recruiting
This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…
Phase: PHASE3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC